Who is sponsoring NCT00300469?

NCT00300469 is sponsored by Abbott.

What condition does NCT00300469 study?

NCT00300469 studies Mixed Dyslipidemia, Coronary Heart Disease, Dyslipidemia.

What drugs are being tested in NCT00300469?

Interventions: ABT-335, Atorvastatin, Placebo.

What is the status of NCT00300469?

NCT00300469 is currently COMPLETED.

Last reviewed 2009-06-01 · How we verify

A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Atorvastatin Calcium Combination Therapy to Fenofibric Acid and Atorvastatin Calcium Monotherapy in Subjects With Mixed Dyslipidemia

NCT00300469 Phase 3 COMPLETED Results posted

The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + atorvastatin combination therapy with ABT-335 and atorvastatin monotherapy in subjects with multiple abnormal lipid levels in the blood.

Details

Lead sponsor	Abbott
Phase	Phase 3
Status	COMPLETED
Enrolment	613
Start date	2006-03

Conditions

Mixed Dyslipidemia
Coronary Heart Disease
Dyslipidemia

Interventions

ABT-335
Atorvastatin
Placebo

Primary outcomes

Mean Percent Change in Triglycerides From Baseline to Final Visit — Baseline to 12 Weeks (Final Visit)
\[(Week 12 triglycerides minus baseline triglycerides)/baseline triglycerides\] x 100
Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit — Baseline to 12 Weeks (Final Visit)
\[(Week 12 HDL-C minus baseline HDL-C)/baseline HDL-C\] x 100
Mean Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Final Visit — Baseline to 12 Weeks (Final Visit)
\[(Week 12 LDL-C minus baseline LDL-C)/baseline LDL-C\] x 100

Countries

United States